AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3598162 — intervention group
Group type: EXPERIMENTAL
Intervention: lactitol (12 g/6 h)
Number of subjects: 40
Study 31793418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol Oil (250 mg CBD/3 fl. oz)
Number of subjects: 29
Study 31793418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29681047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 60
Study 29681047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 60
Study 29681047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28138986 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch training (5 times per week for 6 weeks)
Number of subjects: 11
Study 28138986 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonstretched) of 10 males
Number of subjects: 11
Study 26524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (1 mg s.c. injection three days after embryo transfer)
Number of subjects: 199
Study 26524798 — intervention group
Group type: COMPARATOR
Intervention: No leuprolide acetate (control group)
Number of subjects: 199
Study 23456328 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic anadromes (e.g., sub when bus is the target)
Number of subjects: 0
Study 23456328 — intervention group
Group type: COMPARATOR
Intervention: Unrelated words (well)
Number of subjects: 0
Study 23456328 — intervention group
Group type: COMPARATOR
Intervention: Words that share the same vowel but not the same set of phonemes (sun)
Number of subjects: 0
Study 21323540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (0.625 mg in 0.025 ml of solution)
Number of subjects: 150
Study 21323540 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser therapy
Number of subjects: 150
Study 21323540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 150
Study 17997442 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral estrogen (polyestradiol phosphate)
Number of subjects: 697
Study 17997442 — intervention group
Group type: COMPARATOR
Intervention: Total androgen blockade
Number of subjects: 697
Study 17214343 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach incorporating CA125 as a primary test and ultrasound as a secondary test
Number of subjects: 0
Study 17214343 — intervention group
Group type: COMPARATOR
Intervention: Various screening strategies
Number of subjects: 0
Study 14614166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal endoscopic tracheal occlusion
Number of subjects: 24
Study 14614166 — intervention group
Group type: COMPARATOR
Intervention: Standard postnatal care
Number of subjects: 24
Study 10881252 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal variant frontotemporal dementia (tv‐FTD)
Number of subjects: 35
Study 10881252 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal variant frontotemporal dementia (fv‐FTD)
Number of subjects: 35
Study 10881252 — intervention group
Group type: COMPARATOR
Intervention: Early dementia of Alzheimer type (DAT)
Number of subjects: 35
Study 10881252 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 35
Study 8939347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastalgia (cyclical and characterized by tenderness with pain)
Number of subjects: 1394
Study 8939347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical mastalgia associated with tenderness and pain
Number of subjects: 1394
Study 8939347 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast swelling
Number of subjects: 1394
Study 8939347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastalgia associated with breast swelling
Number of subjects: 1394
Study 1415405 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 437
Study 1415405 — intervention group
Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 437
Study 1415405 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (subgroup vaginal delivery)
Number of subjects: 437
Study 1415405 — intervention group
Group type: COMPARATOR
Intervention: Control (subgroup vaginal delivery)
Number of subjects: 437
Study 1415405 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (subgroup cesarean delivery)
Number of subjects: 437
Study 1415405 — intervention group
Group type: COMPARATOR
Intervention: Control (subgroup cesarean delivery)
Number of subjects: 437
Study 30971374 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention of obesity with a previously trained nurse (G1)
Number of subjects: 123
Study 30971374 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational group with digital platform support and motivated physical activity program (G2)
Number of subjects: 123
Study 29953441 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for one year
Number of subjects: 320
Study 29953441 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 320
Study 29953441 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 320
Study 27618916 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhengtian Capsule
Number of subjects: 360
Study 27618916 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 360
Study 24126172 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher left ventricular ejection fraction or pulse pressure
Number of subjects: 6632
Study 24126172 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased baseline PWV
Number of subjects: 6632
Study 24126172 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mean arterial pressure <90 mm Hg
Number of subjects: 6632
Study 23059435 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (30 min twice a week for 5 weeks)
Number of subjects: 19
Study 23059435 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and Chinese herbs (acupuncture 30 min twice a week for 5 weeks; herbs taken three times a day)
Number of subjects: 19
Study 19110146 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Tissue Plasminogen Activator (rt-PA)
Number of subjects: 1899
Study 19110146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1899
Study 19110146 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS score change
Number of subjects: 1899
Study 19110146 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS score improvement of at least 55% in moderate stroke severity (baseline NIHSS score 7-15)
Number of subjects: 1899
Study 18257968 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS1 (G‐84A_exon 1c promoter polymorphism)
Number of subjects: 95
Study 18257968 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS3 (Glu298Asp)
Number of subjects: 95
Study 15709939 — intervention group
Group type: EXPERIMENTAL
Intervention: Various psychotherapy treatments tested in 236 studies
Number of subjects: 427
Study 15709939 — intervention group
Group type: COMPARATOR
Intervention: Control groups from 427 comparisons
Number of subjects: 427
Study 12854745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)
Number of subjects: 40
Study 12854745 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia without N2O
Number of subjects: 40
Study 9890317 — intervention group
Group type: EXPERIMENTAL
Intervention: Reused dialyzers with various germicides (Renalin, bleach, glutaraldehyde, heated citric acid)
Number of subjects: 0
Study 9890317 — intervention group
Group type: EXPERIMENTAL
Intervention: Reused dialyzers
Number of subjects: 0
Study 9890317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐flux and high‐flux dialyzers
Number of subjects: 0
Study 8787366 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (intramuscular, given for 5 days)
Number of subjects: 84
Study 8787366 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (single oral dose, 25 mg/kg/body-weight)
Number of subjects: 84
Study 2005167 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 100
Study 2005167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 100
Study 6391154 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-g vegetable-protein-supplemented diet (30 g animal and 50 g vegetable, diet B)
Number of subjects: 6
Study 6391154 — intervention group
Group type: COMPARATOR
Intervention: 40-g protein diet (30 g animal and 10 g vegetable, diet A)
Number of subjects: 6
Study 30583813 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB) with bupivacaine
Number of subjects: 65
Study 30583813 — intervention group
Group type: COMPARATOR
Intervention: PAI with bupivacaine:liposomal bupivacaine mixture (LB group)
Number of subjects: 65
Study 30318624 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-QD (once-daily tacrolimus)
Number of subjects: 125
Study 30318624 — intervention group
Group type: COMPARATOR
Intervention: TAC-BID (twice-daily tacrolimus)
Number of subjects: 125
Study 30318624 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-QD
Number of subjects: 125
Study 26459175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g oral daily)
Number of subjects: 60
Study 26459175 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy (PEXG) without metformin
Number of subjects: 60
Study 24176529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling with probiotics
Number of subjects: 256
Study 24176529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling with placebo
Number of subjects: 256
Study 24176529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 256
Study 21876066 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (20-100 mg/kg/d, mean 50.2 mg/kg/d)
Number of subjects: 103
Study 21876066 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam
Number of subjects: 103
Study 18314112 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CC group (100 mg of clomiphene citrate daily starting after medroxyprogesterone acetate for 5 days)
Number of subjects: 212
Study 18314112 — intervention group
Group type: COMPARATOR
Intervention: Late CC group (100 mg of clomiphene citrate daily starting on day 3 of menses for 5 days)
Number of subjects: 212
Study 18314112 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CC group
Number of subjects: 212
Study 18314112 — intervention group
Group type: COMPARATOR
Intervention: Late CC group
Number of subjects: 212
Study 17259062 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived early pubertal maturation
Number of subjects: 1366
Study 17259062 — intervention group
Group type: EXPERIMENTAL
Intervention: Associating with delinquent peers in 6th grade
Number of subjects: 1366
Study 17259062 — intervention group
Group type: EXPERIMENTAL
Intervention: Early maturation
Number of subjects: 1366
Study 15036178 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniofacial growth in CLP group
Number of subjects: 218
Study 15036178 — intervention group
Group type: COMPARATOR
Intervention: Craniofacial growth in normal group
Number of subjects: 218
Study 15036178 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth timing and peak velocity
Number of subjects: 218
Study 11583389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 72
Study 11583389 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 72
Study 9840608 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine administered at six, 10, and 14 weeks
Number of subjects: 0
Study 9840608 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine administered at 10 and 14 weeks
Number of subjects: 0
Study 9840608 — intervention group
Group type: COMPARATOR
Intervention: Control group (meningococcal A/C polysaccharide vaccine)
Number of subjects: 0
Study 9840608 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (group 1)
Number of subjects: 0
Study 9840608 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (group 2)
Number of subjects: 0
Study 9840608 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (both groups)
Number of subjects: 0
Study 7863249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 20 mg/h
Number of subjects: 126
Study 7863249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 10 mg/h
Number of subjects: 126
Study 7863249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 7863249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (both doses)
Number of subjects: 126
Study 7863249 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 126
Study 2510259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms at bedtime for 6 months
Number of subjects: 190
Study 2510259 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg at bedtime for 6 months
Number of subjects: 190
Study 811925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Number of subjects: 0
Study 811925 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0
Study 811925 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 0
Study 811925 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine + Glibenclamide
Number of subjects: 0
Study 31765956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus xiamenensis PM14 inoculation
Number of subjects: 0
Study 31765956 — intervention group
Group type: COMPARATOR
Intervention: Uninoculated plants under 200 mg kg-1 Cr stress
Number of subjects: 0
Study 30426311 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide combined with prednisone
Number of subjects: 100
Study 30426311 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide with concomitant prednisone
Number of subjects: 100
Study 28318624 — intervention group
Group type: EXPERIMENTAL
Intervention: online hemodiafiltration
Number of subjects: 381
Study 28318624 — intervention group
Group type: COMPARATOR
Intervention: high-flux hemodialysis
Number of subjects: 381
Study 25487082 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg administered weekly
Number of subjects: 176
Study 25487082 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg administered every other week
Number of subjects: 176
Study 25487082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 23172889 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy
Number of subjects: 19
Study 21492400 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (1.25 g, 2.5 g, 3.75 g, and 5.0 g)
Number of subjects: 234
Study 21492400 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 234
Study 20307430 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaster slipper (n=20)
Number of subjects: 37
Study 20307430 — intervention group
Group type: COMPARATOR
Intervention: Tubi-grip support (n=17)
Number of subjects: 37
Study 20307430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 16513872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 32
Study 16513872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12809566 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 12809566 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 12809566 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10827314 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique (group M) with cephalad implantation of the graft in the ipsilateral iliac fossa and vascular anastomoses in the common iliac vessels
Number of subjects: 280
Study 10827314 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (group C) with implantation of the kidney in the contralateral iliac fossa and vascular anastomoses on the external iliac vessels
Number of subjects: 280
Study 10827314 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique (group M)
Number of subjects: 280
Study 10827314 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (group C)
Number of subjects: 280
Study 8892364 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 93
Study 8892364 — intervention group
Group type: COMPARATOR
Intervention: Nylidrin
Number of subjects: 93
Study 1992928 — intervention group
Group type: EXPERIMENTAL
Intervention: m-xylene exposure (200 ppm for 4 hours)
Number of subjects: 9
Study 1992928 — intervention group
Group type: COMPARATOR
Intervention: Control session (no m-xylene exposure)
Number of subjects: 9
Study 6828617 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16
Study 6828617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30691085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cola (158 kcal)
Number of subjects: 32
Study 30691085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate milk (224 kcal)
Number of subjects: 32
Study 30691085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit drink (154 kcal)
Number of subjects: 32
Study 30691085 — intervention group
Group type: COMPARATOR
Intervention: Water (0 kcal)
Number of subjects: 32
Study 29447329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine plus capecitabine (VC)
Number of subjects: 770
Study 29447329 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 770
Study 28515068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (target of 20% of energy from fat)
Number of subjects: 48835
Study 28515068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention
Number of subjects: 48835
Study 28515068 — intervention group
Group type: COMPARATOR
Intervention: Usual diet comparison group
Number of subjects: 48835
Study 25559914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose exercise (150 min/week)
Number of subjects: 139
Study 25559914 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose exercise (300 min/week)
Number of subjects: 139
Study 25559914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 139
Study 23432941 — intervention group
Group type: EXPERIMENTAL
Intervention: PTVE + EVL
Number of subjects: 88
Study 23432941 — intervention group
Group type: COMPARATOR
Intervention: EVL
Number of subjects: 88
Study 21619917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolic extract of Tulsi leaves (300 mg capsules)
Number of subjects: 24
Study 21619917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18288059 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel cisplatin (4 cycles followed by 2 cycles of docetaxel alone if objective response or stabilisation)
Number of subjects: 300
Study 18288059 — intervention group
Group type: COMPARATOR
Intervention: docetaxel alone (4 cycles followed by 2 cycles of docetaxel alone if objective response or stabilisation)
Number of subjects: 300
Study 16894950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0
Study 14626181 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Salvia Injection (CSI) plus Western Medicine (WM)
Number of subjects: 72
Study 14626181 — intervention group
Group type: COMPARATOR
Intervention: Western Medicine (WM)
Number of subjects: 72
Study 11099285 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 464
Study 11099285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 464
Study 11099285 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 464
Study 11099285 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling and Cognitive-behaviour therapy
Number of subjects: 464
Study 9417975 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (maximal tolerated dose individually determined)
Number of subjects: 3
Study 9417975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 9417975 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 3
Study 7801547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method of x-ray and radiologic examinations of the lungs
Number of subjects: 0
Study 3522371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (21 mmol sodium per day)
Number of subjects: 140
Study 3522371 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted sodium intake
Number of subjects: 140
Study 29727013 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus, target Cmin range of 5-7 ng/mL initially and 5-15 ng/mL for inadequate response.
Number of subjects: 0
Study 29727013 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus, TN-Cmin increases.
Number of subjects: 0
Study 26227401 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (M)
Number of subjects: 98
Study 26227401 — intervention group
Group type: EXPERIMENTAL
Intervention: Video (V)
Number of subjects: 98
Study 26227401 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 98
Study 24898154 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation
Number of subjects: 30
Study 24898154 — intervention group
Group type: EXPERIMENTAL
Intervention: PureGraft
Number of subjects: 30
Study 24898154 — intervention group
Group type: COMPARATOR
Intervention: Centrifugation and PureGraft
Number of subjects: 30
Study 23931421 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 30
Study 23931421 — intervention group
Group type: COMPARATOR
Intervention: Catheter coronary angiogram (CCA)
Number of subjects: 30
Study 21920335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin monotherapy or atorvastatin-based combination therapies
Number of subjects: 33
Study 18312050 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system patch (10-30 mg, 9-hour wear time)
Number of subjects: 282
Study 18312050 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate capsule (18-54 mg)
Number of subjects: 282